All In Biotech

Drug Trial Radar · NCT04045327

Efficacy of PMZ-2010 (Centhaquine) a Resuscitative Agent for Hypovolemic Shock

A Prospective, Multi-Centric, Randomized, Double-Blind, Parallel, Phase-III Study to Assess Efficacy of PMZ-2010 as a Resuscitative Agent for Hypovolemic Shock to be Used as an Adjuvant to Standard Shock Treatment

Last checked: Nov 20, 2026Latest source record: Oct 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 105 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

105

Actual

Start

Jan 31, 2019

Primary completion

Sep 23, 2019

Study completion Sep 27, 2019

Sponsor

Lead sponsor
Pharmazz, Inc.Industry
Sponsor type
Industry
First posted
Aug 5, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, multi-centric, randomized, double-blind, parallel, controlled phase-III efficacy clinical study of PMZ-2010 therapy in patients with hypovolemic shock. Centhaquine (previously used names, centhaquin and PMZ-2010; International Non-proprietary Name (INN) recently approved by WHO is centhaquine) has been found to be an effective resuscitative agent in rat, rabbit and swine models of hemorrhagic shock, it decreased blood lactate, increased mean arterial pressure, cardiac output, and decreased mortality. An increase in cardiac output during resuscitation is mainly attributed to an increase in stroke volume. Centhaquine acts on the venous α2B-adrenergic receptors and enhances venous return to the heart, in addition, it produces arterial dilatation by acting on central α2A-adrenergic receptors to reduce sympathetic activity and systemic vascular resistance.

Conditions

  • Hypovolemic Shock

Interventions

  • Normal saline + Standard TreatmentDrug

    Normal Saline to be Used as Vehicle in the Phase-III Study to Assess Efficacy of PMZ-2010 as a Resuscitative Agent for Hypovolemic Shock

  • Centhaquine + Standard TreatmentDrug

    Phase-III Study to Assess Efficacy of PMZ-2010 as a Resuscitative Agent for Hypovolemic Shock

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in systolic and diastolic blood pressureTime frame: 48 hours
  2. Change in blood lactate levelTime frame: 48 hours
  3. Change in base-deficitTime frame: 48 hours

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Jawahar Lal Nehru Medical College & Attached Hospitals

    Ajmer, India

  • Radiant Superspeciality Hospital

    Amravati, India

  • People Tree Hospitals

    Bangalore, India

  • KLE's Dr. Prabhakar Kore Hospital & Medical Research Centre

    Belagavi, India

  • Shri Guru Ram Rai Institute of Medical & Health Sciences

    Dehradun, India

  • Department of Surgery, GSVM Medical College

    Kanpur, India

  • Institute of Postgraduate Medical Education & Research and SSKM Hospital

    Kolkata, India

  • King George's Medical University

    Lucknow, India

  • Christian Medical College & Hospital

    Ludhiana, India

  • Sidhu Hospital Pvt. Ltd.

    Ludhiana, India

  • Department of General Medicine, JSS Hospital

    Mysuru, India

  • New Era Hospital & Research Institute

    Nagpur, India

  • Rahate Surgical Hospital & ICU

    Nagpur, India

  • Criticare Hospital & Research Institute

    Nagpur, India

  • ACSR Government Medical College & Hospital

    Nellore, India

  • Maulana Azad Medical College and associated Lok Nayak Hospital

    New Delhi, India

  • Institute of Medical Sciences, Banaras Hindu University

    Varanasi, India

  • Seven Star Hospital

    Nagpur, Maha, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.